Cotrimoxazole treatment for rheumatoid arthritis
Identifieur interne : 002397 ( Main/Exploration ); précédent : 002396; suivant : 002398Cotrimoxazole treatment for rheumatoid arthritis
Auteurs : Alexander Rozin [Israël] ; Daniel Schapira [Israël] ; Yolanda Braun-Moscovici [Israël] ; A. Menachem Nahir [Israël]Source :
- Seminars in Arthritis and Rheumatism [ 0049-0172 ] ; 2001.
English descriptors
- KwdEn :
- Teeft :
- Adverse effects, Alexander rozin, Antimicrobial agents, Arthritis, Arthritis rheum, Autoimmune diseases, Biological agents, Bruce rappaport faculty, Clin, Cotrimoxazole, Cytotoxic drugs, Daily dose, Daniel schapira, Dihydrofolate reductase, Disease activity, Folic acid, Granulomatosis, Grip strength, Hematologic malignancies, Immune process, Immunomodulatory, Immunomodulatory properties, Life span, Lower bowel, Lymphocyte, Lymphocyte population, Medication, Medline search, Methotrexate, Methotrexate therapy, Morning stiffness, Nonsteroidal drugs, Peak serum concentration, Pharmacological basis, Platelet count, Pneumocystis carinii pneumonia, Poor nausea, Positive results, Proteus mirabilis, Rejection time, Rheum, Rheumatic diseases, Rheumatoid, Rheumatoid arthritis, Rheumatol, Rheumatology, Ritchie index, Rozin, Semin arthritis rheum, Serum level, Shine department, Side effects, Skin grafts, Sulfapyridine, Sulfonamide, Temporal arteritis, Therapeutic trial, Ulcerative colitis.
Abstract
Abstract: Objectives: To review the literature on the immunomodulatory and anti-inflammatory properties of cotrimoxazole (CTX)—a combination of sulfamethoxazole and trimethoprim, to summarize the use of this medication in the treatment of autoimmune diseases, to stimulate and renew the interest of both physicians and researchers in this possible therapy for rheumatoid arthritis (RA), and to inspire further investigation in this field. Methods: A MEDLINE search of the literature from 1966 until 2000 was performed, and information about the pharmacology of CTX and its use in the therapy of rheumatic diseases was critically reviewed. Results: RA treatment is associated with numerous problems such as lack of efficacy, frequent side effects, and high cost. Analysis of the relevant literature revealed that experience with CTX in the treatment of RA is limited. However, the results of several nonrandomized and evidently forgotten clinical trials and laboratory investigations suggested that CTX might serve as an effective and inexpensive therapy for RA. Several lines of evidence suggested that CTX has nonspecific anti-inflammatory and immunomodulatory properties. Although nausea and vomiting were common reasons for CTX withdrawal, they were noted in only some studies, and no major organ toxicity was observed. Conclusions: Because of its therapeutic qualities, low cost, and relative nontoxicity, CTX seems to warrant a role in the treatment of RA. Semin Arthritis Rheum 31:133-141. Copyright © 2001 by W.B. Saunders Company
Url:
DOI: 10.1053/sarh.2001.27734
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000517
- to stream Istex, to step Curation: 000517
- to stream Istex, to step Checkpoint: 001223
- to stream Main, to step Merge: 002422
- to stream Main, to step Curation: 002397
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cotrimoxazole treatment for rheumatoid arthritis</title><author><name sortKey="Rozin, Alexander" sort="Rozin, Alexander" uniqKey="Rozin A" first="Alexander" last="Rozin">Alexander Rozin</name></author><author><name sortKey="Schapira, Daniel" sort="Schapira, Daniel" uniqKey="Schapira D" first="Daniel" last="Schapira">Daniel Schapira</name></author><author><name sortKey="Braun Moscovici, Yolanda" sort="Braun Moscovici, Yolanda" uniqKey="Braun Moscovici Y" first="Yolanda" last="Braun-Moscovici">Yolanda Braun-Moscovici</name></author><author><name sortKey="Nahir, A Menachem" sort="Nahir, A Menachem" uniqKey="Nahir A" first="A. Menachem" last="Nahir">A. Menachem Nahir</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6B8F4D2F5B3E1FCBCF634D0193036C21B145EBA9</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1053/sarh.2001.27734</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-6BS1TCST-N/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000517</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000517</idno><idno type="wicri:Area/Istex/Curation">000517</idno><idno type="wicri:Area/Istex/Checkpoint">001223</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001223</idno><idno type="wicri:doubleKey">0049-0172:2001:Rozin A:cotrimoxazole:treatment:for</idno><idno type="wicri:Area/Main/Merge">002422</idno><idno type="wicri:Area/Main/Curation">002397</idno><idno type="wicri:Area/Main/Exploration">002397</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Cotrimoxazole treatment for rheumatoid arthritis</title><author><name sortKey="Rozin, Alexander" sort="Rozin, Alexander" uniqKey="Rozin A" first="Alexander" last="Rozin">Alexander Rozin</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>B. Shine Department of Rheumatology, Rambam Medical Center, and the H. Schussheim Rheumatology Research Laboratory, The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa</wicri:regionArea><wicri:noRegion>Haifa</wicri:noRegion></affiliation></author><author><name sortKey="Schapira, Daniel" sort="Schapira, Daniel" uniqKey="Schapira D" first="Daniel" last="Schapira">Daniel Schapira</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>B. Shine Department of Rheumatology, Rambam Medical Center, and the H. Schussheim Rheumatology Research Laboratory, The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa</wicri:regionArea><wicri:noRegion>Haifa</wicri:noRegion></affiliation></author><author><name sortKey="Braun Moscovici, Yolanda" sort="Braun Moscovici, Yolanda" uniqKey="Braun Moscovici Y" first="Yolanda" last="Braun-Moscovici">Yolanda Braun-Moscovici</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>B. Shine Department of Rheumatology, Rambam Medical Center, and the H. Schussheim Rheumatology Research Laboratory, The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa</wicri:regionArea><wicri:noRegion>Haifa</wicri:noRegion></affiliation></author><author><name sortKey="Nahir, A Menachem" sort="Nahir, A Menachem" uniqKey="Nahir A" first="A. Menachem" last="Nahir">A. Menachem Nahir</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>B. Shine Department of Rheumatology, Rambam Medical Center, and the H. Schussheim Rheumatology Research Laboratory, The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa</wicri:regionArea><wicri:noRegion>Haifa</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Seminars in Arthritis and Rheumatism</title><title level="j" type="abbrev">YSARH</title><idno type="ISSN">0049-0172</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2001">2001</date><biblScope unit="volume">31</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="133">133</biblScope><biblScope unit="page" to="141">141</biblScope></imprint><idno type="ISSN">0049-0172</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0049-0172</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Rheumatoid arthritis</term><term>autoimmune diseases</term><term>cotrimoxazole</term><term>sulfamethoxazole</term><term>trimethoprim</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Adverse effects</term><term>Alexander rozin</term><term>Antimicrobial agents</term><term>Arthritis</term><term>Arthritis rheum</term><term>Autoimmune diseases</term><term>Biological agents</term><term>Bruce rappaport faculty</term><term>Clin</term><term>Cotrimoxazole</term><term>Cytotoxic drugs</term><term>Daily dose</term><term>Daniel schapira</term><term>Dihydrofolate reductase</term><term>Disease activity</term><term>Folic acid</term><term>Granulomatosis</term><term>Grip strength</term><term>Hematologic malignancies</term><term>Immune process</term><term>Immunomodulatory</term><term>Immunomodulatory properties</term><term>Life span</term><term>Lower bowel</term><term>Lymphocyte</term><term>Lymphocyte population</term><term>Medication</term><term>Medline search</term><term>Methotrexate</term><term>Methotrexate therapy</term><term>Morning stiffness</term><term>Nonsteroidal drugs</term><term>Peak serum concentration</term><term>Pharmacological basis</term><term>Platelet count</term><term>Pneumocystis carinii pneumonia</term><term>Poor nausea</term><term>Positive results</term><term>Proteus mirabilis</term><term>Rejection time</term><term>Rheum</term><term>Rheumatic diseases</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatol</term><term>Rheumatology</term><term>Ritchie index</term><term>Rozin</term><term>Semin arthritis rheum</term><term>Serum level</term><term>Shine department</term><term>Side effects</term><term>Skin grafts</term><term>Sulfapyridine</term><term>Sulfonamide</term><term>Temporal arteritis</term><term>Therapeutic trial</term><term>Ulcerative colitis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Objectives: To review the literature on the immunomodulatory and anti-inflammatory properties of cotrimoxazole (CTX)—a combination of sulfamethoxazole and trimethoprim, to summarize the use of this medication in the treatment of autoimmune diseases, to stimulate and renew the interest of both physicians and researchers in this possible therapy for rheumatoid arthritis (RA), and to inspire further investigation in this field. Methods: A MEDLINE search of the literature from 1966 until 2000 was performed, and information about the pharmacology of CTX and its use in the therapy of rheumatic diseases was critically reviewed. Results: RA treatment is associated with numerous problems such as lack of efficacy, frequent side effects, and high cost. Analysis of the relevant literature revealed that experience with CTX in the treatment of RA is limited. However, the results of several nonrandomized and evidently forgotten clinical trials and laboratory investigations suggested that CTX might serve as an effective and inexpensive therapy for RA. Several lines of evidence suggested that CTX has nonspecific anti-inflammatory and immunomodulatory properties. Although nausea and vomiting were common reasons for CTX withdrawal, they were noted in only some studies, and no major organ toxicity was observed. Conclusions: Because of its therapeutic qualities, low cost, and relative nontoxicity, CTX seems to warrant a role in the treatment of RA. Semin Arthritis Rheum 31:133-141. Copyright © 2001 by W.B. Saunders Company</div></front></TEI><affiliations><list><country><li>Israël</li></country></list><tree><country name="Israël"><noRegion><name sortKey="Rozin, Alexander" sort="Rozin, Alexander" uniqKey="Rozin A" first="Alexander" last="Rozin">Alexander Rozin</name></noRegion><name sortKey="Braun Moscovici, Yolanda" sort="Braun Moscovici, Yolanda" uniqKey="Braun Moscovici Y" first="Yolanda" last="Braun-Moscovici">Yolanda Braun-Moscovici</name><name sortKey="Nahir, A Menachem" sort="Nahir, A Menachem" uniqKey="Nahir A" first="A. Menachem" last="Nahir">A. Menachem Nahir</name><name sortKey="Schapira, Daniel" sort="Schapira, Daniel" uniqKey="Schapira D" first="Daniel" last="Schapira">Daniel Schapira</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002397 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002397 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:6B8F4D2F5B3E1FCBCF634D0193036C21B145EBA9
|texte= Cotrimoxazole treatment for rheumatoid arthritis
}}
| This area was generated with Dilib version V0.6.33. |  |